TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Incidence of acute post-ERCP pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ambient Wideband Absorbance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Generalized Anxiety Disorder severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angle differences between pre-operative plan and final implant position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Upper Extremity Component of Fugl-Meyer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease or Treatment-related Morbidity and Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in Subjective Daytime Sleepiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sleep Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical Condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximally tolerated dose of alpelisib
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended phase 2 dose of alpelisib
Endpoint domain: Adverse events/effects
Primary endpoint: Cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Complement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual pain response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Score for Common Cold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in PD2 (Provocative Dose of Aspirin That Elicits an Increase in Nasal Symptom Score of 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline Expression Levels of COX-2 Transcript and Protein in Peripheral Blood Leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Preliminary efficacy of FBTA05
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of new HepB diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Median rating of the liking of all meals
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median rating of feelings of fullness after the meals
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Median perception of healthiness of all meals
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: T cell immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Combined clinical and radiological remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnea based on NYHA classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient BPRS Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Patient perception of nausea
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient perception of pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PSA50 Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cumulative Visual Analog Score for Pain at 1st Follow Up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Visual Analog Score for Pain at Final Follow Up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: metabolic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Preterm birth before 34 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: Psychiatric symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Cocaine craving
Endpoint domain: Adverse events/effects
Primary endpoint: Visual Analog Scale of Pain Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of no major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity of qualitative [18F]GP1 PET/CT interpretation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Any new ctDNA mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Total Visualization Score of Qualitative Endocardial Border Delineation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perception of Intervention Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perception of Intervention Appropriateness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perception of Intervention Feasibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neonatal hearing screening results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-hospital Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Office Systolic Blood Pressure Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Joint bleeding frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTCAE Grade 4 or higher infusion reaction
Endpoint domain: Adverse events/effects
Primary endpoint: CTCAE Grade 4 or higher infection
Endpoint domain: Adverse events/effects
Primary endpoint: malignancy other than non-melanoma skin cancer or HCC recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: rejection resulting in recipient death or retransplantation
Endpoint domain: Adverse events/effects
Primary endpoint: biopsy-proven severe acute rejection
Endpoint domain: Adverse events/effects
Primary endpoint: any grade chronic rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of SPECT-CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC Fluticasone Propionate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective tumor response (complete or partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: % of patients reaching goal HbA1C (<7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: % of patients with BP goal (<130/80)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: % of patients with LDL at goal (<100)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urethral/pelvic blood flow perfusion pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: naive CD4+ and CD8+ T cell numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TREC positive recent thymic emigrants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum tolerated dose (MTD) of TQ-B3234
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-limiting toxicity(ies) (DLT[s]) of TQ-B3234
Endpoint domain: Adverse events/effects
Primary endpoint: Change in IDS Symptom Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PMTS Symptom Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CGI-S Symptom Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in DRSP Symptom Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CGI Improvement Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary metastatic progression-free rate
Endpoint domain: Mortality/survival
Primary endpoint: Participant Pain Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotion recognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Irritation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1 year pejorative evolution
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Causality of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Firing activity of single units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants needed rescue agents
Endpoint domain: Adverse events/effects
Primary endpoint: Total accumulated energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate control in patients with atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perception of intestinal gas infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in objective cognitive functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in word fluency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Implant Success
Endpoint domain: Mortality/survival
Primary endpoint: PCA3 Score Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in gut peptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in diet induced thermogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in satiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of complementary exams
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: clinical attachment level (CAL) regained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity/specificity of PSOCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of bone formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequency of prescription of extended-duration post-discharge thromboprophylaxis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Detection of precancers or early cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Post-operative analgesia consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of injury/illness
Endpoint domain: Adverse events/effects
Primary endpoint: nonfatal stroke (ischemic or hemorrhagic)
Endpoint domain: Mortality/survival
Primary endpoint: Predictability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-assessment of emotion regulation capability after training
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in heart rate variability after training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of neovascular subtype exhibiting persistent disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CoaguChek point-of-care testing result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Parasite multiplication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Score of neurological deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharmacokinetics of IV lorazepam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative blood flow changes of the oral mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuroimaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BiAffect Metric
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Amount of MRD detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Feasibility of Parent and Family obesity interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of Parent and Family obesity interventions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient experiences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lung Collapse Index (LCI) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cmax of BNZ in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of BNZ in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of BNZ in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall efficacy rate of the enema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum hormone levels of Ethinyl estradiol and levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: MicroRNA levels in serum samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Assessment by Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical healing of the palate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence with COVID19 transmission containment measures
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Unintended health, social and economic consequences of government response
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Efficacy of government interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FAZA PET uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reversal of anticoagulation measured by WBCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician Administered PTSD Scale (CAPS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: World Health Organization Quality of Life (WHOQOL-BREF) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the drug-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in endothelium-dependent vasodilation of the microcirculation of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement in endothelium-dependent vasodilation of the brachial artery (flow mediated dilation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement in selective measurements of oxidative stress, endothelial activity and vascular abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of responders after initial treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactivation rate for all patients
Endpoint domain: Adverse events/effects
Primary endpoint: thickness of limbus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of tobacco users receiving help
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With Non-Candida Invasive Fungal Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum dose tolerated
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Incidence of Treatment Related Major Adverse Cardiac Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in right ventricular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Tricuspid Regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of treated bleeding episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Antenatal Psychosocial Health Assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pregnancy Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical Activity during Pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of Breast Mass Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Combined Score of symptoms and allergy medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion rate of quarterly visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion with at least one diagnosed STI
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of an unwanted pregnancy in the last 12 months
Endpoint domain: Adverse events/effects
Primary endpoint: Volumetric changes in complicated vascular anomalies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time of clinical lab indexes to be improved and stable
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Brief Psychotic Rating Scale (BPRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Objective Response Rate (CR + PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of patients for which national guidelines were followed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tolerance to neoadjuvant therapy
Endpoint domain: Adverse events/effects
Primary endpoint: success of peripheral vein access positioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Endothelial function (flow mediated dilatation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean post-operative daily pain at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measured resting energy expenditure (mREE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients recovered from arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hemangioma thickness variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with HbA1c <7% and no symptomatic hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in IC-Q symptom index (ICSI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacokinetic profile of tolbutamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success Rate - SUI Symptom Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Continuous Glucose Monitoring Glucose (CGMG) Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Time Spent With CGMG Concentration < 60 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of vaginal sexual intercourse
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction of gastrointestinal toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Weight-Loss Maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants in Need for Bank Blood Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safe and well tolerated dose of MT1002
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Abnormal Findings in Physical Examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Vital Signs of Potential Clinical Concern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hypoglycaemic events <70 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Marginal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patient satisfaction using VAS questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Behavioral Approach Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes